Wells Fargo Reiterates Buy Rating on ZYME
Wells Fargo reaffirmed its buy rating on ZYME, setting a $37 price target, a 39.15% upside from the current price.
Key Points
- Wells Fargo reiterated its buy rating for ZYME, maintaining a price target of $37 as of June 30, 2026.
- Wells Fargo's $37 price target implies 39.15% upside from Zymeworks Inc.'s ($ZYME) current $26.59 share price.
- ZYME shares traded at $26.59 on Tuesday, reflecting ongoing interest from institutional investors.
- Recent insider buying activity includes purchases by executives Paul Schneider and Scott Platshon in April and May 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Wells Fargo reiterated its buy rating on ZYME, setting a price target of $37. This reaffirmation reflects continued confidence in the company's outlook.
Wells Fargo vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ZYME
ECOR1 Capital, LLC maintained its substantial stake in ZYME with 22,970,388 shares valued at approximately $575.2 million. Rubric Capital Management LP increased its holdings by 1,250,000 shares, bringing its total to 7,000,000 shares worth about $175.3 million, marking a 21.7% increase. BlackRock, Inc. slightly reduced its position by 41,660 shares, ending with 4,553,888 shares valued at $114.0 million, a decrease of 0.9%. BVF Inc/IL also trimmed its stake by 204,499 shares, now holding 3,734,142 shares worth roughly $93.5 million, a 5.2% reduction. Meanwhile, Perceptive Advisors LLC boosted its holdings by 248,228 shares to 3,510,078 shares, valued at approximately $87.9 million, a 7.6% increase.
Insider Buying and Selling at Zymeworks Inc.
Recent insider activity at ZYME includes significant buying by executives. On May 13, 2026, Paul Schneider, EVP and General Counsel, purchased 178,000 shares, followed by an additional 119,000 shares on the same day. Earlier, on April 9, 2026, Scott Platshon, EVP and Chief Business Officer, acquired 76,000 shares and then 47,000 more, while Adam Schayowitz, EVP and Head of Research & Development, bought 47,000 shares, followed by 76,000 shares later that day.
Analysts Set New Price Targets
On June 30, 2026, Wells Fargo maintained its buy rating for ZYME with a $37 price target. Earlier, on May 8, 2026, Wells Fargo reiterated a buy rating with a $34 target. Other firms like Evercore ISI Group, HC Wainwright & Co., Stifel, and Leerink Partners have maintained buy ratings with targets ranging from $46 to $58. Truist Securities initiated coverage with a buy rating and a $40 target on December 17, 2025.
Bottom Line
Wells Fargo's reaffirmation of its buy rating on ZYME, along with a $37 price target, indicates a positive outlook for the company. Institutional investors are actively managing their positions, with some increasing and others reducing their stakes. Recent insider buying activity suggests confidence from company executives. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and investors should consider a range of factors when evaluating a stock.
Get Zymeworks Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZYME, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.